The Role of IGFBP-3 in Tumor Development and Progression: Enlightenment for Diagnosis and Treatment

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2024 May 7

PMID 38714554

Authors

Yudi Wang

He Zhang

Xuehua Zhang

Peizheng Mu

Leilei Zhao

Ruomei Qi

Yurui Zhang

Xiao Zhu

Yucui Dong

Affiliations

Soon will be listed here.

Abstract

IGFBP-3 is aberrantly expressed in many tumor types, and its serum and tumor tissue levels provide auxiliary information for assessing the degree of tumor malignancy and patient prognosis, making it a potential therapeutic target for human malignancies and conferring it remarkable clinical value for determining patient prognosis. In this review, we provide a comprehensive overview of the aberrant expression, diverse biological effects, and clinical implications of IGFBP-3 in tumors and its role as a potential prognostic marker and therapeutic target for tumors. In addition, we summarize the signaling pathways through which IGFBP-3 exerts its effects. IGFBP-3 comprises an N-terminal, an intermediate region, and a C-terminal structural domain, each exerting different biological effects in several tumor cell types in an IGF-dependent/non-independent manner. IGFBP-3 shares an intricate relationship with the tumor microenvironment, thereby affecting tumor growth. Overall, IGFBP-3 is an essential regulatory factor that mediates tumor occurrence and progression. Gaining deeper insights into the fundamental characteristics of IGFBP-3 and its role in various tumor types will provide new perspectives and allow for the development of novel strategies for cancer diagnosis, treatment, and prognostic evaluation.

References

LeRoith D, Roberts Jr C . The insulin-like growth factor system and cancer. Cancer Lett. 2003; 195(2):127-37. DOI: 10.1016/s0304-3835(03)00159-9. View

Rajaram S, Baylink D, Mohan S . Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev. 1997; 18(6):801-31. DOI: 10.1210/edrv.18.6.0321. View

Ding H, Wu T . Insulin-Like Growth Factor Binding Proteins in Autoimmune Diseases. Front Endocrinol (Lausanne). 2018; 9:499. PMC: 6125368. DOI: 10.3389/fendo.2018.00499. View

Abdolhoseinpour H, Mehrabi F, Shahraki K, Khoshnood R, Masoumi B, Yahaghi E . Investigation of serum levels and tissue expression of two genes IGFBP-2 and IGFBP-3 act as potential biomarker for predicting the progression and survival in patients with glioblastoma multiforme. J Neurol Sci. 2016; 366:202-206. DOI: 10.1016/j.jns.2016.05.018. View

Rosenfeld R, Hwa V, Wilson E, Plymate S, Oh Y . The insulin-like growth factor-binding protein superfamily. Growth Horm IGF Res. 2000; 10 Suppl A:S16-7. DOI: 10.1016/s1096-6374(00)90007-8. View

Bhattacharyya N, Pechhold K, Shahjee H, Zappala G, Elbi C, Raaka B . Nonsecreted insulin-like growth factor binding protein-3 (IGFBP-3) can induce apoptosis in human prostate cancer cells by IGF-independent mechanisms without being concentrated in the nucleus. J Biol Chem. 2006; 281(34):24588-601. DOI: 10.1074/jbc.M509463200. View

Fujimoto M, Khoury J, Khoury P, Kalra B, Kumar A, Sluss P . Anthropometric and biochemical correlates of PAPP-A2, free IGF-I, and IGFBP-3 in childhood. Eur J Endocrinol. 2020; 182(3):363-374. PMC: 7238294. DOI: 10.1530/EJE-19-0859. View

Dang Y, Huang G, Chen Y, Dang Z, Chen C, Liu F . Sulforaphane inhibits the proliferation of the BIU87 bladder cancer cell line via IGFBP-3 elevation. Asian Pac J Cancer Prev. 2014; 15(4):1517-20. DOI: 10.7314/apjcp.2014.15.4.1517. View

Zhou N, Sun Z, Li N, Ge Y, Zhou J, Han Q . miR‑197 promotes the invasion and migration of colorectal cancer by targeting insulin‑like growth factor‑binding protein 3. Oncol Rep. 2018; 40(5):2710-2721. DOI: 10.3892/or.2018.6640. View

10.

Oh S, Lee O, Schroeder C, Oh Y, Ke S, Cha H . Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition. Mol Cancer Ther. 2006; 5(11):2685-95. DOI: 10.1158/1535-7163.MCT-06-0142. View

11.

Yu H, Rohan T . Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 2000; 92(18):1472-89. DOI: 10.1093/jnci/92.18.1472. View

12.

Marimuthu A, Chavan S, Sathe G, Sahasrabuddhe N, Srikanth S, Renuse S . Identification of head and neck squamous cell carcinoma biomarker candidates through proteomic analysis of cancer cell secretome. Biochim Biophys Acta. 2013; 1834(11):2308-16. DOI: 10.1016/j.bbapap.2013.04.029. View

13.

Zhang X, Wang G, Gong Y, Zhao L, Song P, Zhang H . IGFBP3 induced by the TGF-β/EGFRvIII transactivation contributes to the malignant phenotype of glioblastoma. iScience. 2023; 26(5):106639. PMC: 10182331. DOI: 10.1016/j.isci.2023.106639. View

14.

Yang L, Li J, Fu S, Ren P, Tang J, Wang N . Up-regulation of Insulin-like Growth Factor Binding Protein-3 Is Associated with Brain Metastasis in Lung Adenocarcinoma. Mol Cells. 2019; 42(4):321-332. PMC: 6530643. DOI: 10.14348/molcells.2019.2441. View

15.

Jogie-Brahim S, Feldman D, Oh Y . Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev. 2009; 30(5):417-37. PMC: 2819737. DOI: 10.1210/er.2008-0028. View

16.

Yamada P, Lee K . Perspectives in mammalian IGFBP-3 biology: local vs. systemic action. Am J Physiol Cell Physiol. 2009; 296(5):C954-76. DOI: 10.1152/ajpcell.00598.2008. View

17.

Baxter R . IGF binding proteins in cancer: mechanistic and clinical insights. Nat Rev Cancer. 2014; 14(5):329-41. DOI: 10.1038/nrc3720. View

18.

Johnson M, Firth S . IGFBP-3: a cell fate pivot in cancer and disease. Growth Horm IGF Res. 2014; 24(5):164-73. DOI: 10.1016/j.ghir.2014.04.007. View

19.

Yan X, Forbes B, McNeil K, Baxter R, Firth S . Role of N- and C-terminal residues of insulin-like growth factor (IGF)-binding protein-3 in regulating IGF complex formation and receptor activation. J Biol Chem. 2004; 279(51):53232-40. DOI: 10.1074/jbc.M409345200. View

20.

Buckway C, Wilson E, Ahlsen M, Bang P, Oh Y, Rosenfeld R . Mutation of three critical amino acids of the N-terminal domain of IGF-binding protein-3 essential for high affinity IGF binding. J Clin Endocrinol Metab. 2001; 86(10):4943-50. DOI: 10.1210/jcem.86.10.7936. View